OraSure Technologies (OSUR) Appoints Jack Kenny to its Board

September 9, 2024 7:05 AM EDT

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure’s Board of Directors currently has seven members.

Mr. Kenny is the former Chief Executive Officer for Meridian Bioscience, where he led the company’s turnaround before it was acquired. He has more than 30 years of experience with leadership roles in the in vitro diagnostics, molecular, and lab services industries. He will serve as a Class I Director with an initial term expiring at OraSure’s 2025 Annual Meeting of Stockholders.

“We recognize the significant value and industry expertise that Jack will contribute, and we are pleased to continue to strengthen our Board with his participation,” said Mara Aspinall, Chair of the Board of Directors of OraSure. “Under our leadership team led by President and CEO Carrie Eglinton Manner, we have made meaningful progress on our journey to strengthen our foundation, elevate our core growth, and accelerate our profitability. We look forward to the value Jack will add to the company.”

Before his tenure at Meridian, Mr. Kenny served as Senior Vice President and General Manager, North America, with Siemens Healthcare and as Vice President and General Manager, U.S. Region, for Becton Dickinson, Diagnostic Systems. Prior to that, he held executive roles at Danaher Corporation and Quest Diagnostics.

Mr. Kenny’s operational experience in the diagnostics field is broad, including product management, commercial leadership, and acquisition integration. He holds a bachelor’s degree in management from Kettering University.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Board Changes, Corporate News

Related Entities

Definitive Agreement, Maynard Um, Mark Zuckerberg, FDA, ARK